Autoantibodies neutralizing thrombopoietin in a patient with a megakaryocytic thrombocytopenic purpura

Abstract

Amegakaryocytic thrombocytopenic purpura (AMTP), first reported by Korn,[1][1] is a rare disease characterized by severe thrombocytopenia associated with a total absence or a selective decrease in bone marrow megakaryocytes. Previous studies suggest a variety of pathogenetic mechanisms for AMTP,